Effects of Acute Colchicine Administration Prior to Percutaneous Coronary Intervention: COLCHICINE-PCI Randomized Trial

Circulation: Cardiovascular Interventions

Volumn 13, Issue 4, 2020, Pages E008717-

  Shah, Binita ^a,b   Pillinger, Michael ^a,b   Zhong, Hua ^b   Cronstein, Bruce ^b   Xia, Yuhe ^b   Lorin, Jeffrey D ^a,b   Smilowitz, Nathaniel R ^a,b   Feit, Frederick ^b   Ratnapala, Nicole ^b   Keller, Norma M ^b   Katz, Stuart D ^b  

^a VA New York Harbor HCS   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biomarker; colchicine; inflammation; myocardial infarction; percutaneous coronary intervention

Indexed keywords

ANTIINFLAMMATORY AGENT; AUTACOID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; COLCHICINE; IL6 PROTEIN, HUMAN; INTERLEUKIN 6;

ACUTE CORONARY SYNDROME; ADVERSE EVENT; AGED; BLOOD; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEVICES; DIAGNOSTIC IMAGING; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; FEMALE; HUMAN; INFLAMMATION; MALE; METABOLISM; MIDDLE AGED; MORTALITY; NEW YORK; ORAL DRUG ADMINISTRATION; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STENT; TIME FACTOR; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ADMINISTRATION, ORAL; AGED; ANTI-INFLAMMATORY AGENTS; BIOMARKERS; C-REACTIVE PROTEIN; COLCHICINE; CORONARY ARTERY DISEASE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; MIDDLE AGED; NEW YORK CITY; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; RISK FACTORS; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85083477423     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.119.008717     Document Type: Article

References (45)

1. Inoue T, Sakai Y, Morooka S, Hayashi T, Takayanagi K, Takabatake Y. Expression of polymorphonuclear leukocyte adhesion molecules and its clinical significance in patients treated with percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1996;28:1127-1133. doi: 10.1016/S0735-1097(96)00308-7
2. Welt FG, Edelman ER, Simon DI, Rogers C. Neutrophil, not macrophage, infiltration precedes neointimal thickening in balloon-injured arteries. Arterioscler Thromb Vasc Biol. 2000;20:2553-2558. doi: 10.1161/01.atv.20.12.2553
3. Rogers C, Welt FG, Karnovsky MJ, Edelman ER. Monocyte recruitment and neointimal hyperplasia in rabbits. Coupled inhibitory effects of heparin. Arterioscler Thromb Vasc Biol. 1996;16:1312-1318. doi: 10.1161/01.atv.16.10.1312
4. Shu J, Ren N, Du JB, Zhang M, Cong HL, Huang TG. Increased levels of interleukin-6 and matrix metalloproteinase-9 are of cardiac origin in acute coronary syndrome. Scan Cardiovasc J. 2007;41:149-154. doi:10.1080/14017430601164263
5. Robertson L, Grip L, Mattsson Hultén L, Hulthe J, Wiklund O. Release of protein as well as activity of MMP-9 from unstable atherosclerotic plaques during percutaneous coronary intervention. J Intern Med. 2007;262:659-667. doi: 10.1111/j.1365-2796.2007.01861.x
6. Aggarwal A, Schneider DJ, Terrien EF, Gilbert KE, Dauerman HL. Increase in interleukin-6 in the first hour after coronary stenting: an early marker of the inflammatory response. J Thromb Thrombolysis. 2003;15:25-31. doi: 10.1023/a:1026188200939
7. Sardella G, Accapezzato D, Di Roma A, Iacoboni C, Francavilla V, Benedetti G, Musto C, Fedele F, Bruno G, Paroli M. Integrin beta2-chain (CD18) over-expression on CD4+ T cells and monocytes after ischemia/ reperfusion in patients undergoing primary percutaneous revascularization. Int J Immunopathol Pharmacol. 2004;17:165-170. doi: 10.1177/039463200401700208
8. Munk PS, Breland UM, Aukrust P, Skadberg O, Ueland T, Larsen AI. Inflammatory response to percutaneous coronary intervention in stable coronary artery disease. J Thromb Thrombolysis. 2011;31:92-98. doi: 10.1007/s11239-010-0471-7
9. Buffon A, Liuzzo G, Biasucci LM, Pasqualetti P, Ramazzotti V, Rebuzzi AG, Crea F, Maseri A. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol. 1999;34:1512-1521. doi: 10.1016/s0735-1097(99)00348-4
10. Walter DH, Fichtlscherer S, Sellwig M, Auch-Schwelk W, Schächinger V, Zeiher AM. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol. 2001;37:839-846. doi: 10.1016/s0735-1097(00)01193-1
11. Kwaijtaal M, van Diest R, Bär FW, van der Ven AJ, Bruggeman CA, de Baets MH, Appels A. Inflammatory markers predict late cardiac events in patients who are exhausted after percutaneous coronary intervention. Atherosclerosis. 2005;182:341-348. doi: 10.1016/j.atherosclerosis.2005.02.022
12. Patti G, Di Sciascio G, D'Ambrosio A, Dicuonzo G, Abbate A, Dobrina A. Prognostic value of interleukin-1 receptor antagonist in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2002;89:372-376. doi: 10.1016/s0002-9149(01)02254-8
13. Kotooka N, Inoue T, Fujimatsu D, Morooka T, Hashimoto S, Hikichi Y, Uchida T, Sugiyama A, Node K. Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening. Atherosclerosis. 2008;197:368-374. doi: 10.1016/j.atherosclerosis.2007.05.031
14. Inoue T, Uchida T, Sakuma M, Imoto Y, Ozeki Y, Ozaki Y, Hikichi Y, Node K. Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. J Am Coll Cardiol. 2004;44:1408-1414. doi: 10.1016/j.jacc.2004.06.066
15. Shah B, Baber U, Pocock SJ, Krucoff MW, Ariti C, Gibson CM, Steg PG, Weisz G, Witzenbichler B, Henry TD, et al. White blood cell count and major adverse cardiovascular events after percutaneous coronary intervention in the contemporary era: insights from the PARIS study. Circ Cardiovasc Interv. 2017;10:e004981. doi: 10.1161/CIRCINTERVENTIONS.117.004981
16. Novack V, Pencina M, Cohen DJ, Kleiman NS, Yen CH, Saucedo JF, Berger PB, Cutlip DE. Troponin criteria for myocardial infarction after percutaneous coronary intervention. Arch Intern Med. 2012;172:502-508. doi: 10.1001/archinternmed.2011.2275
17. Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheum. 2009;38:411-419. doi: 10.1016/j.semarthrit.2008.08.006
18. Paschke S, Weidner AF, Paust T, Marti O, Beil M, Ben-Chetrit E. Technical advance: inhibition of neutrophil chemotaxis by colchicine is modulated through viscoelastic properties of subcellular compartments. J Leukoc Biol. 2013;94:1091-1096. doi: 10.1189/jlb.1012510
19. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237-241. doi: 10.1038/nature04516
20. Rudolph SA, Greengard P, Malawista SE. Effects of colchicine on cyclic AMP levels in human leukocytes. Proc Natl Acad Sci U S A. 1977;74:3404-3408. doi: 10.1073/pnas.74.8.3404
21. Cronstein BN, Molad Y, Reibman J, Balakhane E, Levin RI, Weissmann G. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest. 1995;96:994-1002. doi: 10.1172/JCI118147
22. Shah B, Allen N, Harchandani B, Pillinger M, Katz S, Sedlis SP, Echagarruga C, Samuels SK, Morina P, Singh P, et al. Effect of colchicine on platelet-platelet and platelet-leukocyte interactions: a Pilot Study in Healthy Subjects. Inflammation. 2016;39:182-189. doi: 10.1007/s10753-015-0237-7
23. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: twentyfour-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62:1060-1068. doi: 10.1002/art.27327
24. Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol. 2009;54:558-565. doi: 10.1016/j.jacc.2009.05.028
25. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Katus HA, Lindahl B, Morrow DA, Clemmensen PM, et al; Joint ESC/ ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. Circulation. 2012;126:2020-2035. doi: 10.1161/CIR.0b013e31826e1058
26. Moussa ID, Klein LW, Shah B, Mehran R, Mack MJ, Brilakis ES, Reilly JP, Zoghbi G, Holper E, Stone GW. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). J Am Coll Cardiol. 2013;62:1563-1570. doi: 10.1016/j.jacc.2013.08.720
27. Briguori C, Visconti G, Focaccio A, Golia B, Chieffo A, Castelli A, Mussardo M, Montorfano M, Ricciardelli B, Colombo A. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural MI: results from the NAPLES II trial. J Am Coll Cardiol. 2009;54:2157-2163. doi: 10.1016/j.jacc.2009.07.005
28. Matsubara T, Ishibashi T, Hori T, Ozaki K, Mezaki T, Tsuchida K, Nasuno A, Kubota K, Tanaka T, Miida T, et al. Association between coronary endothelial dysfunction and local inflammation of atherosclerotic coronary arteries. Mol Cell Biochem. 2003;249:67-73.
29. Gupta SK, Johnson RM, Mather KJ, Clauss M, Rehman J, Saha C, Desta Z, Dubé MP. Anti-inflammatory treatment with pentoxifylline improves HIVrelated endothelial dysfunction: a pilot study. AIDS. 2010;24:1377-1380. doi: 10.1097/QAD.0b013e3283396024
30. Götz AK, Zahler S, Stumpf P, Welsch U, Becker BF. Intracoronary formation and retention of micro aggregates of leukocytes and platelets contribute to postischemic myocardial dysfunction. Basic Res Cardiol. 2005;100:413-421. doi: 10.1007/s00395-005-0540-9
31. Ren F, Mu N, Zhang X, Tan J, Li L, Zhang C, Dong M. Increased plateletleukocyte aggregates are associated with myocardial no-reflow in patients with ST elevation myocardial infarction. Am J Med Sci. 2016;352:261-266. doi: 10.1016/j.amjms.2016.05.034
32. Nidorf M, Thompson PL. Effect of colchicine (0.5 mg twice daily) on highsensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am J Cardiol. 2007;99:805-807. doi: 10.1016/j.amjcard.2006.10.039
33. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G; ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation. 2004;110:674-678. doi: 10.1161/01.CIR.0000137828.06205.87
34. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, Montinaro A, Di Sciascio G. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 2007;49:1272-1278. doi: 10.1016/j.jacc.2007.02.025
35. Patti G, Chello M, Pasceri V, Colonna D, Nusca A, Miglionico M, D'Ambrosio A, Covino E, Di Sciascio G. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J Am Coll Cardiol. 2006;48:1560-1566. doi: 10.1016/j.jacc.2006.06.061
36. Patti G, Chello M, Gatto L, Alfano G, Miglionico M, Covino E, Di Sciascio G. Short-term atorvastatin preload reduces levels of adhesion molecules in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Results from the ARMYDA-ACS CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J Cardiovasc Med (Hagerstown). 2010;11:795-800. doi: 10.2459/JCM.0b013e32833b929c
37. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, et al; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119-1131. doi: 10.1056/NEJMoa1707914
38. Borden WB, Redberg RF, Mushlin AI, Dai D, Kaltenbach LA, Spertus JA. Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention. JAMA. 2011;305:1882-1889. doi: 10.1001/jama.2011.601
39. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther. 2006;28:26-35. doi: 10.1016/j. clinthera.2006.01.005
40. Martínez GJ, Robertson S, Barraclough J, Xia Q, Mallat Z, Bursill C, Celermajer DS, Patel S. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome. J Am Heart Assoc. 2015;4:e002128. doi: 10.1161/JAHA.115.002128
41. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61:404-410. doi: 10.1016/j.jacc.2012.10.027
42. Crittenden DB, Lehmann RA, Schneck L, Keenan RT, Shah B, Greenberg JD, Cronstein BN, Sedlis SP, Pillinger MH. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol. 2012;39:1458-1464. doi: 10.3899/jrheum.111533
43. Deftereos S, Giannopoulos G, Raisakis K, Kossyvakis C, Kaoukis A, Panagopoulou V, Driva M, Hahalis G, Pyrgakis V, Alexopoulos D, et al. Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients. J Am Coll Cardiol. 2013;61:1679-1685. doi: 10.1016/j.jacc. 2013.01.055
44. Ozer I, Mete T, Turkeli Sezer O, Kolbasi Ozgen G, Kucuk GO, Kaya C, Kilic Kan E, Duman G, Ozturk Kurt HP. Association between colchicine resistance and vitamin D in familial Mediterranean fever. Ren Fail. 2015;37:1122-1125. doi: 10.3109/0886022X.2015.1056064
45. Tufan A, Babaoglu MO, Akdogan A, Yasar U, Calguneri M, Kalyoncu U, Karadag O, Hayran M, Ertenli AI, Bozkurt A, et al. Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever. J Rheumatol. 2007;34:1540-1544.